12/9
07:30 am
rlmd
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Low
Report
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
12/6
05:31 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
12/6
05:31 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Mizuho from a "strong-buy" rating to a "hold" rating.
Low
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Mizuho from a "strong-buy" rating to a "hold" rating.
12/5
08:02 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $10.00.
High
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $10.00.
12/5
08:01 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $1.00 price target on the stock, down previously from $23.00.
High
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $1.00 price target on the stock, down previously from $23.00.
11/25
05:34 pm
rlmd
Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsight [Yahoo! Finance]
Low
Report
Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsight [Yahoo! Finance]
11/21
01:34 pm
rlmd
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
11/19
09:14 am
rlmd
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
11/19
09:00 am
rlmd
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Medium
Report
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
11/14
07:39 am
rlmd
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]
Low
Report
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]
11/14
07:30 am
rlmd
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
Low
Report
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
11/8
02:48 am
rlmd
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
11/7
04:32 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/7
04:23 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/7
04:10 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/4
04:30 pm
rlmd
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Low
Report
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024